Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis
Solid organ transplant recipients were demonstrated to have reduced antibody response to the first and second doses of the COVID-19 mRNA vaccine. This review evaluated published data on the efficacy and safety of the third dose among solid organ transplant recipients. We performed a systematic searc...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/10/1/95 |
_version_ | 1797489866443849728 |
---|---|
author | Orly Efros Roi Anteby Mirit Halfon Eshcar Meisel Eyal Klang Shelly Soffer |
author_facet | Orly Efros Roi Anteby Mirit Halfon Eshcar Meisel Eyal Klang Shelly Soffer |
author_sort | Orly Efros |
collection | DOAJ |
description | Solid organ transplant recipients were demonstrated to have reduced antibody response to the first and second doses of the COVID-19 mRNA vaccine. This review evaluated published data on the efficacy and safety of the third dose among solid organ transplant recipients. We performed a systematic search of PubMed, EMBASE, and Web of Science to retrieve studies evaluating the efficacy of the third dose of anti-SARS-CoV-2 vaccines in adult solid organ transplant recipients. Serologic response after the third vaccine was pooled using inverse variance and generalized linear mixed and random-effects models. Seven studies met our inclusion criteria. A total of 853 patients received the third dose. Except for one randomized controlled trial, all studies were retrospective in design. Following the third COVID-19 vaccine dose, antibody response occurred in 6.4–69.2% of patients. The pooled proportion of antibody response rate after the third vaccine was 50.3% (95% confidence interval (CI): 37.1–63.5, I<sup>2</sup> = 90%). Five papers reported the safety profile. No severe adverse events were observed after the third vaccine dose. In conclusion, a third dose of the SARS-CoV-2 mRNA vaccine in solid organ transplant recipients is associated with improved immunogenicity and appears to be safe. Nevertheless, a significant portion of patients remain seronegative. |
first_indexed | 2024-03-10T00:22:44Z |
format | Article |
id | doaj.art-5d9bd8b625e2417897d7d796705b8452 |
institution | Directory Open Access Journal |
issn | 2076-393X |
language | English |
last_indexed | 2024-03-10T00:22:44Z |
publishDate | 2022-01-01 |
publisher | MDPI AG |
record_format | Article |
series | Vaccines |
spelling | doaj.art-5d9bd8b625e2417897d7d796705b84522023-11-23T15:39:20ZengMDPI AGVaccines2076-393X2022-01-011019510.3390/vaccines10010095Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-AnalysisOrly Efros0Roi Anteby1Mirit Halfon2Eshcar Meisel3Eyal Klang4Shelly Soffer5National Hemophilia Center, Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat-Gan 5262100, IsraelSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, IsraelSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, IsraelSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, IsraelSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, IsraelInternal Medicine Department B, Assuta Medical Center, Ben-Gurion University of the Negev, Be’er Sheva 8410501, IsraelSolid organ transplant recipients were demonstrated to have reduced antibody response to the first and second doses of the COVID-19 mRNA vaccine. This review evaluated published data on the efficacy and safety of the third dose among solid organ transplant recipients. We performed a systematic search of PubMed, EMBASE, and Web of Science to retrieve studies evaluating the efficacy of the third dose of anti-SARS-CoV-2 vaccines in adult solid organ transplant recipients. Serologic response after the third vaccine was pooled using inverse variance and generalized linear mixed and random-effects models. Seven studies met our inclusion criteria. A total of 853 patients received the third dose. Except for one randomized controlled trial, all studies were retrospective in design. Following the third COVID-19 vaccine dose, antibody response occurred in 6.4–69.2% of patients. The pooled proportion of antibody response rate after the third vaccine was 50.3% (95% confidence interval (CI): 37.1–63.5, I<sup>2</sup> = 90%). Five papers reported the safety profile. No severe adverse events were observed after the third vaccine dose. In conclusion, a third dose of the SARS-CoV-2 mRNA vaccine in solid organ transplant recipients is associated with improved immunogenicity and appears to be safe. Nevertheless, a significant portion of patients remain seronegative.https://www.mdpi.com/2076-393X/10/1/95COVID-19vaccinesthird dosesolid organ transplant recipients |
spellingShingle | Orly Efros Roi Anteby Mirit Halfon Eshcar Meisel Eyal Klang Shelly Soffer Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis Vaccines COVID-19 vaccines third dose solid organ transplant recipients |
title | Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis |
title_full | Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis |
title_fullStr | Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis |
title_full_unstemmed | Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis |
title_short | Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis |
title_sort | efficacy and safety of third dose of the covid 19 vaccine among solid organ transplant recipients a systemic review and meta analysis |
topic | COVID-19 vaccines third dose solid organ transplant recipients |
url | https://www.mdpi.com/2076-393X/10/1/95 |
work_keys_str_mv | AT orlyefros efficacyandsafetyofthirddoseofthecovid19vaccineamongsolidorgantransplantrecipientsasystemicreviewandmetaanalysis AT roianteby efficacyandsafetyofthirddoseofthecovid19vaccineamongsolidorgantransplantrecipientsasystemicreviewandmetaanalysis AT mirithalfon efficacyandsafetyofthirddoseofthecovid19vaccineamongsolidorgantransplantrecipientsasystemicreviewandmetaanalysis AT eshcarmeisel efficacyandsafetyofthirddoseofthecovid19vaccineamongsolidorgantransplantrecipientsasystemicreviewandmetaanalysis AT eyalklang efficacyandsafetyofthirddoseofthecovid19vaccineamongsolidorgantransplantrecipientsasystemicreviewandmetaanalysis AT shellysoffer efficacyandsafetyofthirddoseofthecovid19vaccineamongsolidorgantransplantrecipientsasystemicreviewandmetaanalysis |